Application of Herschler
Decision Date | 01 February 1979 |
Docket Number | Appeal No. 78-548. |
Citation | 591 F.2d 693 |
Parties | In the Matter of the Application of Robert J. HERSCHLER. |
Court | U.S. Court of Customs and Patent Appeals (CCPA) |
Stanley M. Teigland, attorney of record, San Francisco, Cal., for appellant.
Joseph F. Nakamura, Washington, D. C., for the Commissioner of Patents; Fred W. Sherling, Associate Sol. Ernest G. Therkorn, Washington, D. C., of counsel.
Before RICH, BALDWIN and MILLER, Judges, and KASHIWA* and FORD,** Judges.
This appeal is from the decision of the Patent and Trademark Office (PTO) Board of Appeals (board) affirming the rejection of claims 1-5 and 9-13 in appellant's application serial No. 304,283,1 filed November 6, 1972, for "Enhancing Tissue Penetration of Physiologically Active Steroidal Agents with DMSO."2
The board affirmed the examiner's rejection of all claims under 35 U.S.C. § 103 as unpatentable over Lubowe in view of Faust, Marson or Brown. The board also affirmed a rejection, first entered pursuant to its authority under 37 C.F.R. § 1.196(b),3 of each of the claims under 35 U.S.C. §§ 102(b) or 103 over Stroughton et al., Stroughton or Kligman.4 We reverse.
The appellant has found that DMSO enhances the penetration of a number of materials through skin tissue. In the application at hand, a mixture of DMSO and a "physiologically active steroidal agent" is administered to skin (or a mucous membrane) with the result that the steroid penetrates the membrane. The claimed process provides such advantages as the elimination of injection by needle and the ability to administer localized doses of the drug without resort to a systemic dose.
Claim 1 is typical of the invention:
1. A method of enhancing the penetration into and across an external membrane barrier of a human or animal subject of a physiologically active steroidal agent capable of eliciting a physiological effect upon topical application thereof, which comprises the concurrent topical administration to the external membrane of an amount of said steroidal agent effective to produce the desired physiological effect and an amount of DMSO sufficient to effectively enhance penetration of said steroidal agent to achieve the desired physiological effect.
The following references were relied upon to support the rejection under § 103:
Lubowe is a patent directed to compositions with large amounts of mineral, vegetable or animal oils solubilized in short chain alcohols. The oils are maintained in solution by the addition of fatty alcohols having 10 to 24 carbon atoms. The resulting compositions may be used as a base in a number of further cosmetic and pharmaceutical compositions. When the composition is used in a hair lotion, Lubowe indicates that "estrogenic hormones, methyl sulfoxide" may be added. Example XII shows a hair lotion containing 0.1% estrogenic hormone in 50% ethyl alcohol but without DMSO.
Brown et al. shows DMSO to be a solvent in which many classes of compounds are soluble and, further, is of low toxicity.
Faust suggests that DMSO is a "safe and effective solubilizing" agent suitable for use as a cosmetic or dermatologic vehicle.
Marson cites Faust saying "the cosmetic literature has recently cited its DMSO's employment as simple, non-gelated components of dermatological vehicles" and describes the usefulness of DMSO in preparing pharmaceutical compositions containing, inter alia, the thickening agents such as recited in the claims.
The examiner indicated in the Final Rejection and in his Answer that the claims were rejected under 35 U.S.C. § 103 since "the Lubowe patent describes, inter alia, DMSO added to Ex. XII, an anti-seborrheic hair lotion containing 1/10 part by weight of estrogenic hormone," and that, "we have, inherently, the same process involved here as described in Lubowe, notwithstanding applicant's observation of percutaneous absorption from the DMSO (apparently added as a vehicle or solvent, according to Faust, Marson or Brown)."
The board, in a first opinion, agreed with the Examiner's position and amplified it, stating:
Appellant thereupon submitted a Request for Reconsideration accompanied by two attachments and requested that the examiner consider them. The first attachment was a portion of a 508 page collection of papers given at a conference entitled Conference on Biological Actions of Dimethyl Sulfoxide held by the New York Academy of Sciences in 1974. The second enclosure was a copy of a Rule 45 declaration5 submitted in the great-grandparent application purporting to amend the inventorship from Jacob and Herschler joint to Herschler sole.
In support of the Rule 45 affidavit, appellant argued:
With respect to the first reason, submitted herewith are copies of papers filed under Rule 45 in the great-grandparent application, and a copy of a postcard receipt indicating that the papers were received by the Patent Office. The papers include an amendment under Rule 45 to change the inventorship of the great-grandparent application to correspond to the inventorship of this application. No notice was received that entry of the amendment was refused. Moreover, the Rule 45 papers were filed simultaneously with a continuing application in the name of the new inventorship and the Patent Office accorded continuation-in-part status to the application, which issued as U.S.P. 3,551,554. Hence, it is evident that the examiner considered the papers filed under Rule 45 and acknowledged that they were legally sufficient to change the inventorship. However, if the examiner believes it is necessary to formally change the inventorship of the great-grandparent application, he is invited to enter the Rule 45 amendment nunc pro tunc.
Appellant further argued that the written description in the great-grandparent was adequate for the subgenus now claimed:
As clearly indicated in the great-grandparent application, appellant recognized from the start that the invention was applicable to physiologically active agents in general. * * * Thus, the Board's contention that "the only disclosure in the great-grandparent application relating to steroids is limited to glucocorticosteroids" is incorrect. The great-grandparent application discloses that the invention...
To continue reading
Request your trial-
Ralston Purina Co. v. Far-Mar-Co, Inc.
...skill in the art will recognize from the disclosure that applicant's invented processes included those limitations. Application of Herschler, 591 F.2d 693, 701 (CCPA 1979); Application of Wertheim, supra at 262; Application of Smythe, 480 F.2d 1376, 1382 (CCPA 1973). Put another way, the di......
-
Erfindergemeinschaft UroPep GbR v. Eli Lilly & Co.
...of representative compounds is one way to meet the written description requirement, but not the only way. See, e.g., In re Herschler, 591 F.2d 693, 701 (C.C.P.A. 1979) (specification's disclosure of a single example species was sufficient because numerous species were known to skilled artis......
-
Enzo Biochem, Inc. v. Gen-Probe Inc.
...it does, then the claim is entitled to the filing date of the parent application under 35 U.S.C. § 120." Id. at 1351. 13. In re Herschler, 591 F.2d 693 (CCPA 1979). "[A]ppellant concedes that the substance of this rejection is proper if the court finds either the great-grandparent applicati......
-
Leesona Corporation v. Varta Batteries, Inc.
...own foreign patent can work against him in this regard. In re Ruscetta, 255 F.2d 687, 689-90 (C.C.P.A.1958). See also In re Herschler, 591 F.2d 693, 696 (C.C.P.A.1979) ("It is now well settled law that disclosure of a species is insufficient to provide descriptive support for a generic or s......